Tissue Historical Income Statement

TRX Stock

58.50 1.50 2.50%

Historical analysis of Tissue Regenix income statement accounts such as Gross Profit of 17 M, Other Operating Expenses of 36.1 M, EBITDA of 421.5 K or Total Operating Expenses of 10.6 M can show how well Tissue Regenix Group performed in making a profits. Evaluating Tissue Regenix income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tissue Regenix's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Tissue Regenix Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tissue Regenix Group is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Tissue Income Statement Analysis

Tissue Regenix Group Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tissue Regenix shareholders. The income statement also shows Tissue investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Tissue Regenix Income Statement Chart

At present, Tissue Regenix's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 17 M, whereas Selling General Administrative is forecasted to decline to about 10.2 M.

Selling General Administrative Total Revenue Other Operating Expenses Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Tissue Regenix Group generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tissue Regenix Group. It is also known as Tissue Regenix overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Tissue Regenix's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tissue Regenix Group current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Tissue Regenix income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Net Income From Continuing Ops	Cost Of Revenue	Minority Interest	Selling And Marketing Expenses	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.62	0.51	0.85	0.81	0.88	0.39	0.32	0.39	0.61	0.26	-0.28	0.24	0.35	-0.52	0.35	0.87	-0.29	-0.76	0.78	-0.84	-0.78	0.88
Interest Expense	0.62		0.09	0.87	0.87	0.72	0.79	0.74	0.77	0.21	0.75	-0.18	0.73	0.74	-0.69	0.8	0.86	0.19	-0.62	0.86	-0.62	-0.89	0.66
Selling General Administrative	0.51	0.09		0.36	0.36	0.52	-0.15	-0.21	-0.16	0.72	-0.26	-0.38	-0.28	-0.15	0.09	-0.02	0.36	-0.04	-0.19	0.27	-0.33	-0.3	0.34
Total Revenue	0.85	0.87	0.36		1.0	0.94	0.68	0.63	0.68	0.47	0.59	-0.29	0.56	0.64	-0.62	0.7	1.0	0.09	-0.74	0.92	-0.77	-0.97	0.79
Gross Profit	0.81	0.87	0.36	1.0		0.94	0.67	0.63	0.68	0.48	0.6	-0.28	0.57	0.64	-0.59	0.72	0.99	0.13	-0.7	0.91	-0.72	-0.96	0.75
Other Operating Expenses	0.88	0.72	0.52	0.94	0.94		0.4	0.35	0.41	0.72	0.31	-0.26	0.28	0.4	-0.37	0.51	0.94	0.0	-0.71	0.83	-0.7	-0.88	0.75
Operating Income	0.39	0.79	-0.15	0.68	0.67	0.4		0.95	0.95	-0.27	0.94	-0.24	0.93	0.87	-0.9	0.79	0.68	0.25	-0.48	0.71	-0.57	-0.73	0.52
Ebit	0.32	0.74	-0.21	0.63	0.63	0.35	0.95		1.0	-0.28	0.99	0.04	0.99	0.86	-0.8	0.86	0.62	0.41	-0.3	0.65	-0.42	-0.67	0.53
Ebitda	0.39	0.77	-0.16	0.68	0.68	0.41	0.95	1.0		-0.22	0.98	0.02	0.98	0.86	-0.82	0.86	0.67	0.37	-0.35	0.69	-0.48	-0.72	0.59
Total Operating Expenses	0.61	0.21	0.72	0.47	0.48	0.72	-0.27	-0.28	-0.22		-0.31	-0.09	-0.34	-0.18	0.23	0.0	0.46	-0.16	-0.4	0.36	-0.33	-0.42	0.4
Income Before Tax	0.26	0.75	-0.26	0.59	0.6	0.31	0.94	0.99	0.98	-0.31		0.08	1.0	0.87	-0.77	0.87	0.58	0.45	-0.26	0.63	-0.36	-0.65	0.5
Total Other Income Expense Net	-0.28	-0.18	-0.38	-0.29	-0.28	-0.26	-0.24	0.04	0.02	-0.09	0.08		0.11	-0.06	0.34	0.14	-0.3	0.41	0.45	-0.21	0.42	0.24	0.02
Net Income	0.24	0.73	-0.28	0.56	0.57	0.28	0.93	0.99	0.98	-0.34	1.0	0.11		0.83	-0.76	0.86	0.55	0.45	-0.23	0.59	-0.34	-0.61	0.48
Income Tax Expense	0.35	0.74	-0.15	0.64	0.64	0.4	0.87	0.86	0.86	-0.18	0.87	-0.06	0.83		-0.72	0.74	0.64	0.38	-0.44	0.76	-0.44	-0.71	0.57
Research Development	-0.52	-0.69	0.09	-0.62	-0.59	-0.37	-0.9	-0.8	-0.82	0.23	-0.77	0.34	-0.76	-0.72		-0.55	-0.64	0.03	0.58	-0.63	0.71	0.65	-0.55
Net Income From Continuing Ops	0.35	0.8	-0.02	0.7	0.72	0.51	0.79	0.86	0.86	0.0	0.87	0.14	0.86	0.74	-0.55		0.68	0.55	-0.3	0.71	-0.38	-0.75	0.55
Cost Of Revenue	0.87	0.86	0.36	1.0	0.99	0.94	0.68	0.62	0.67	0.46	0.58	-0.3	0.55	0.64	-0.64	0.68		0.05	-0.77	0.93	-0.8	-0.97	0.81
Minority Interest	-0.29	0.19	-0.04	0.09	0.13	0.0	0.25	0.41	0.37	-0.16	0.45	0.41	0.45	0.38	0.03	0.55	0.05		0.32	0.2	0.21	-0.18	0.0
Selling And Marketing Expenses	-0.76	-0.62	-0.19	-0.74	-0.7	-0.71	-0.48	-0.3	-0.35	-0.4	-0.26	0.45	-0.23	-0.44	0.58	-0.3	-0.77	0.32		-0.76	0.91	0.77	-0.61
Tax Provision	0.78	0.86	0.27	0.92	0.91	0.83	0.71	0.65	0.69	0.36	0.63	-0.21	0.59	0.76	-0.63	0.71	0.93	0.2	-0.76		-0.78	-0.96	0.85
Interest Income	-0.84	-0.62	-0.33	-0.77	-0.72	-0.7	-0.57	-0.42	-0.48	-0.33	-0.36	0.42	-0.34	-0.44	0.71	-0.38	-0.8	0.21	0.91	-0.78		0.79	-0.72
Net Interest Income	-0.78	-0.89	-0.3	-0.97	-0.96	-0.88	-0.73	-0.67	-0.72	-0.42	-0.65	0.24	-0.61	-0.71	0.65	-0.75	-0.97	-0.18	0.77	-0.96	0.79		-0.77
Reconciled Depreciation	0.88	0.66	0.34	0.79	0.75	0.75	0.52	0.53	0.59	0.4	0.5	0.02	0.48	0.57	-0.55	0.55	0.81	0.0	-0.61	0.85	-0.72	-0.77

Click cells to compare fundamentals

Tissue Regenix Account Relationship Matchups

Tissue Regenix income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	762K	793.3K	921.4K	977K	1.1M	1.2M
Interest Expense	445K	503.2K	670.6K	1.1M	1.0M	1.0M
Selling General Administrative	12.9M	12.5M	13.3M	14.4M	16.6M	10.2M
Total Revenue	12.8M	14.4M	19.9M	29.5M	33.9M	35.6M
Gross Profit	5.1M	5.6M	9.1M	14.0M	16.1M	17.0M
Other Operating Expenses	16.9M	17.3M	21.5M	29.9M	34.4M	36.1M
Operating Income	(4.1M)	(3.0M)	(1.6M)	(394K)	(453.1K)	(475.8K)
Ebit	(9.8M)	(3.0M)	(1.6M)	(531K)	(477.9K)	(501.8K)
Ebitda	(9.0M)	(2.2M)	(690.9K)	446K	401.4K	421.5K
Total Operating Expenses	9.3M	8.6M	10.8M	14.4M	16.6M	10.6M
Income Before Tax	(10.2M)	(3.7M)	(2.3M)	(1.3M)	(1.2M)	(1.3M)
Total Other Income Expense Net	(6.1M)	639.2K	(285.9K)	(948.7K)	(1.1M)	(1.1M)
Net Income	(9.7M)	(3.5M)	(2.2M)	(1.7M)	(1.5M)	(1.6M)
Income Tax Expense	(533K)	(114.2K)	(188.3K)	(12K)	(10.8K)	(11.3K)
Net Income From Continuing Ops	(9.7M)	(5.0M)	(2.6M)	(1.7M)	(1.9M)	(2.0M)
Cost Of Revenue	7.7M	8.7M	10.7M	15.5M	17.8M	18.7M
Net Income Applicable To Common Shares	(7.0M)	(9.7M)	(4.8M)	(2.7M)	(3.1M)	(3.3M)
Minority Interest	(614K)	193K	(99K)	(56K)	(50.4K)	(52.9K)
Selling And Marketing Expenses	456.5K	3.9M	2.5M	2.8M	2.5M	3.2M
Tax Provision	(533K)	(157K)	(232K)	(12K)	(13.8K)	(14.5K)
Interest Income	2K	3K	8K	26K	23.4K	28.9K
Net Interest Income	(443K)	(689K)	(818K)	(1.3M)	(1.1M)	(1.1M)
Reconciled Depreciation	762K	1.1M	1.1M	977K	1.1M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Other Information on Investing in Tissue Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tissue Historical Income Statement

About Tissue Income Statement Analysis

Tissue Regenix Income Statement Chart

Total Revenue

Other Operating Expenses

Total Operating Expenses

Tissue Regenix income statement Correlations

Tissue Regenix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tissue Regenix income statement Accounts

Also Currently Popular

Other Information on Investing in Tissue Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Cost Of Revenue	+ 0.99	Gross Profit
Income Before Tax	+ 0.99	Ebit

Net Interest Income	- 0.97	Cost Of Revenue
Net Interest Income	- 0.97	Total Revenue
Net Interest Income	- 0.96	Tax Provision
Net Interest Income	- 0.96	Gross Profit
Research Development	- 0.9	Operating Income
Net Interest Income	- 0.89	Interest Expense